CRYPTOLOGY-ASSET-GROUP
3.6.2021 09:59:05 CEST | Business Wire | Press release
Cryptology Asset Group (ISIN: MT0001770107; Ticker: CAP:GR), a leading European investment company for blockchain- and crypto-related businesses founded by Christian Angermayer and Mike Novogratz, intends to invest USD 100 million over the next 24 months into crypto-related venture funds.
Cryptology will take an entrepreneurial approach in building its fund portfolio and will focus on first time funds and emerging managers, globally, including seeding funds and taking stakes in GPs as well.
Christian Angermayer, Founder of Cryptology, explains: "We are at the very beginning of the crypto revolution, and we strive to become one of the leading global investors in this very nascent asset class. Our fund investment strategy will focus on emerging talent, taking a global approach, and will encompass both funds investing in equity stakes of crypto- and blockchain related companies as well as funds investing in crypto assets and tokens."
Patrick Lowry, CEO of Cryptology, adds: "There is no better asset class to bet on than crypto, in my opinion. Within just three years, Cryptology has grown invested capital of approx. EUR 27 million into an NAV of approx. EUR 450 million, as of June 1, 2021. This results in an estimated IRR of more than 300% per year, which is an impressive testimony to the tectonic shift we are seeing in front of our very eyes. We will work hard to continue this success story in the coming years and decades.
Patrick further elaborates: "With regards to our fund investment strategy, our vision is to collaborate closely with our portfolio funds, offering them access to our broad network and experience, as well as to co-invest alongside them into innovative blockchain companies and crypto assets."
Cryptology is one of the few stock-market listed investment companies exclusively focusing on crypto and blockchain related businesses, trading on multiple German exchanges under the ticker symbol CAP:GR and ISIN MT0001770107.
Cryptology offers retail and institutional investors unparalleled and easy access, via its daily liquid shares, to an exclusive asset class that is otherwise reserved for a small group of investors, given that most companies and funds in the crypto sector are still private. For example, Cryptology offers indirect participation in iconic crypto giant Block.one, the publishers of EOSIO, and their newly announced exchange, BULLISH.
Cryptology's fund investment strategy will strengthen its position as the leading access stock to a global, diversified crypto portfolio.
About Cryptology Asset Group p.l.c.
Cryptology is a leading European investment company for crypto assets and blockchain-related business models. Founded by Christian Angermayer's family office, Apeiron Investment Group and crypto-legend Mike Novogratz, Cryptology is the largest publicly traded holding company for blockchain- and crypto-based business models in Europe. Noteworthy portfolio companies include crypto-giant and EOSIO software publisher Block.one, leading HPC provider Northern Data, commission-free online neobroker nextmarkets, and crypto asset management group Iconic Funds.
| Language: | English | |
| Company: | Cryptology Asset Group PLC | |
| Beatrice 66 & 67, Amery Street | ||
| SLM 1707 Sliema | ||
| Malta | ||
| E-mail: | info@cryptology-ag.com | |
| Internet: | cryptology-ag.com | |
| ISIN: | MT0001770107 | |
| WKN: | A2JDEW | |
| Listed: | Regulated Unofficial Market in Dusseldorf | |
| EQS News ID: | 1203868 |
View source version on businesswire.com: https://www.businesswire.com/news/home/20210603005409/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom